HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Development of skills for end-of-life discussions ‘a lifelong process’

Editorial

Provocative data reveal changing paradigms in prostate cancer

Derek Raghavan, MD, PhD

FDA News

FDA grants fast track status to luspatercept for beta-thalassemia

FDA grants fast track status to AG-120 for IDH1-mutated AML

FDA grants fast track designation to sacituzumab govitecan for NSCLC

FDA grants fast track designation to evofosfamide for advanced pancreatic cancer

FDA grants fast track status to TRC105 for metastatic renal cell carcinoma

FDA grants orphan drug designation to Triolimus for angiosarcoma

FDA grants orphan drug designation to Liposomal Grb-2 for AML

In the Journals

Hodgkin’s lymphoma survivors face high risk for cardiovascular diseases

Improved AML prognosis with NPM1-positive FLT3-ITD-negative genotype contingent upon patient age

Sickle cell disease increases mortality risk during pregnancy

TITRe2: Restrictive transfusion threshold not superior to liberal strategy after cardiac surgery

9-valent HPV vaccine noninferior to quadrivalent HPV vaccine

LUSI: Early recall rates decline in subsequent lung cancer screenings

Late mortality rates have declined in pediatric cancer survivors

Investigation programs needed for study of risks in use of pediatric anticoagulant drugs

Clinical data indicate patient-specific risks for chemotherapy-related hospitalization

Institution Notes

Magazine recognizes ‘extraordinary’ nurse

Cancer center director receives award

ASH awards ‘bridge grants’

Center director receives award

Urological society presents Distinguished Service Award

Meeting Highlights

Oncology nurses showcase ‘passion for excellence’ at 40th ONS Congress

Paula T. Rieger, RN, MSN, CAE, FAAN

Meeting News Coverage

Pembrolizumab demonstrates efficacy in advanced head and neck cancers

Anastrozole prolongs breast cancer-free survival following DCIS diagnosis

Aspirin provides survival benefit as secondary preventative measure in colorectal cancer

Speaker: Cost of cancer drugs a 'major problem'

Radiotherapy plus hormone therapy improves PFS after radical prostatectomy

Docetaxel improves survival for men with hormone-naive prostate cancer

Eribulin improves survival for patients with advanced liposarcoma, leiomyosarcoma

Nivolumab-based treatments slow progression of melanoma

Findings support wider excision margins in melanoma

Mutational load predicts progression in patients with Barrett's esophagus

Margin shaving reduces positive margins, need for additional surgery in breast cancer

Pharmacology Consult

Host genetic variants as predictors of chemotherapy-related toxicity in children with ALL: Personalizing the benefit–risk balance

Jai N. Patel, PharmD

morganatic-roan
morganatic-roan